CFDE Data Portal | Search D21S2088E

	Label	Description
	D21S2088E Gene (Entity type)	ENSG00000228592 - D21S2088E
	D21S2088E associations Collection (Entity type)	Associations for D21S2088E_associations
	D21S2088E associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE252944 AKT inhibition 3 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE218378 PBX1 overexpression HCT 116 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE133087 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213611 NUF2 knockdown OVCAR-3 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 11 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

D21S2088E

ENSG00000228592 - D21S2088E

D21S2088E associations

Associations for D21S2088E_associations

D21S2088E associations.tsv

A file from IDG as part of the Harmonizome project

GSE252944 AKT inhibition 3 v 6 human dn

A Gene Set from LINCS

GSE218378 PBX1 overexpression HCT 116 1 v 0 human dn

A Gene Set from LINCS

GSE133087 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE213611 NUF2 knockdown OVCAR-3 1 v 0 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 11 v 9 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 3 v 1 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 3 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.